Asian Free Trade Deal Could Strengthen Canadian Patent Rights, PhRMA Says
This article was originally published in PharmAsia News
Brand industry hopes weaknesses in Canada’s intellectual property regime, including lack of patent term restoration and a higher patent utility standard for biopharmaceutical products, could be addressed through the 11-nation talks on a Trans-Pacific Partnership agreement.
You may also be interested in...
The generic drug trade association’s cross-cutting priorities are the result of an extensive strategic planning process, CEO Ralph Neas says; the group is planning outreach to Congress and the executive branch to highlight the role generic drugs can play in helping to address the nation’s fiscal problems.
At a House hearing PhRMA representative cites the need for 12 years test data exclusivity for biologics in the Trans-Pacific Partnership Agreement. Separately, USTR issues its 2012 Special 301 Report.